医学
托珠单抗
回顾性队列研究
中东
甲状腺
验光服务
格雷夫斯病
还原(数学)
眼病
外科
儿科
东南
梅德林
眼科
Graves眼病
普通外科
标识
DOI:10.1080/08820538.2025.2606981
摘要
To compare the efficacy and safety of teprotumumab and tocilizumab in different stages of thyroid eye disease (TED) patients in the United Arab Emirates (UAE).Methods A retrospective analysis of 44 TED patients (22 teprotumumab, 2023–2025 at Sheikh Shakhbout Medical City and 22 tocilizumab, 2018–2024 at Sheikh Khalifa Medical City) was conducted. Outcomes included proptosis reduction (Hertel exophthalmometry), clinical activity score (CAS) improvement, diplopia improvement, quality of life (QoL) improvement (TED-QOL), recurrence rates, and adverse events. Mann-Whitney U tests and chi-square/Fisher’s exact tests were used (p < .05).Results Teprotumumab produced greater mean proptosis reduction (2.55 ± 1.01 mm vs 2.07 ± 1.07 mm, p = .04) and a larger mean CAS improvement (5.18 ± 1.99 vs 4.59 ± 1.82, p = .34). Diplopia improvement occurred in 78.6% vs 75.0% of patients (p = .82), while ≥1-grade improvement by Gorman criteria was achieved in 59.1% of each group (p = .61). Quality-of-life improvement averaged 4.2 ± 1.4 vs 3.4 ± 1.5 points (p = .18). Disease recurrence was lower with teprotumumab (4.5% vs 13.6%, p = .28). Adverse events occurred in 54.5% (teprotumumab) and 43.5% (tocilizumab) patients (p = .47), and were generally mild and reversible.Conclusion Teprotumumab and tocilizumab improved TED outcomes, with teprotumumab showing trends toward better proptosis reduction and lower recurrence. Larger studies are needed to confirm these findings.
科研通智能强力驱动
Strongly Powered by AbleSci AI